Bristol-Myers Squibb BMY Supply Agreements — Royalty Income

Similar metrics at other companies

PTH

PTHSZELSUVMI Royalty Agreement — Royalty agreement, milestone

$5M+300%

PTH

PTHSZELSUVMI Royalty Agreement — Income received through royalty

30%+22.5pp

PTH

PTHSZELSUVMI Royalty Agreement — Royalty agreement, percent of sales

13%—

SPRYRevenue Under Supply Agreements — Revenue

$2.74M—

PVL

PVLARoyalty Agreement Liability

$19.8M+50.5%

ESP

ESPRRoyalty Purchase Agreement

$72.6M+1.0%

FAQ

What is Bristol-Myers Squibb's supply agreements — royalty income?

Bristol-Myers Squibb (BMY) reported supply agreements — royalty income of $300M in Q4 2025.

How has Bristol-Myers Squibb's supply agreements — royalty income changed year-over-year?

Bristol-Myers Squibb's supply agreements — royalty income decreased by 0.0% year-over-year, from $300M to $300M.

What is the long-term trend for Bristol-Myers Squibb's supply agreements — royalty income?

Over 4 years (2021 to 2025), Bristol-Myers Squibb's supply agreements — royalty income has grown at a 13.4% compound annual growth rate (CAGR), from $725M to $1.2B.

What does supply agreements — royalty income mean?

This metric represents the revenue generated from licensing intellectual property and providing supply chain support to third-party partners. It reflects the monetization of proprietary drug formulations and manufacturing capabilities through contractual arrangements where the company receives a percentage of sales or fixed fees. This income stream is a key indicator of the company's ability to leverage its R&D portfolio beyond direct commercialization.